Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOP Plus Rituximab vs CHOP Plus Tositumomab in Newly Diagnosed Follicular Non-Hodgkin's Lymphoma
NCT00006721Phase 3Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Mar 2001
- Primary completion
- Sep 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab and tositumomab in follicular lymphoma (FL) (3 arms), sponsored by SWOG Cancer Research Network. Primary endpoints: Progression-free Survival at 5 years and Overall Survival at 5 years. Started Mar 2001; status: completed.
02
Drugs
rituximabtositumomab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00006721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006721.